Y obtainable on web-site.Henskens et al. Thrombosis Journal (2018) 16:Page 7 ofAbbreviations APTT: Activated Partial Thromboplastin Time; CT: Closure time; DOAC: Direct oral anticoagulants; INR: International Normalized Ratio; LC-MS: Liquid chromatography with mass spectrometry; MUMC +: Maastricht University Health-related Center; NVAF: Non-valvular atrial fibrillation; PT: Prothrombin time; TT: Thrombin time; VKA: Vitamin K antagonists; VTE: Venous thromboembolism Acknowledgements None7.eight.9.10. Funding No funding was obtained for this article. 11. Availability of information and materials The dataset supporting the conclusions of this article is out there upon request by contacting the corresponding author. Authors’ contributions Conceived an made the study: YMCH, HTC, ATC, SS and HJC. Collected the information: RvO, RW, PV, HS, YMCH, ATC. Wrote the analyses program and analyzed and interpreted the information: YMCH, ATC. Wrote and corrected the paper: YMCH, AJWG, RvO, RW, PH, HS, SS, HJC, HTC and ATC. All authors read and approved the final manuscript. Ethics approval and consent to participate The Institutional Critique Board from the MUMC approved this study (December 2011, project number 114069). Consent for publication Not applicable Competing interests HTC is consultant at Stago. The other authors state that they’ve no conflicts of interests. 12.13.14.15.16.17.18.Publisher’s NoteSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Author information 1 Central Diagnostic Laboratory, Maastricht University Healthcare Centre (MUMC +), Maastricht, The Netherlands. 2Laboratory for Clinical Thrombosis and Hemostasis, Internal medicine, CARIM, Maastricht, The Netherlands. three Department of Cardiology, Cardiovascular center MUMC+, Maastricht, The Netherlands. 4Internal medicine, MUMC+, Maastricht, The Netherlands. five Thrombosis Experience Centre, Vascular medicine, Cardiovascular Centre MUMC+, Maastricht, The Netherlands. Received: 20 October 2017 Accepted: 29 December 2017 23. References 1. van den Besselaar AM. Standardization with the prothrombin time in oral anticoagulant control. Haemostasis. 1985;15(four):271. 2. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6): 11167. three. Mueck W, Schwers S, Stampfuss J. Rivaroxaban and also other novel oral anticoagulants: pharmacokinetics in healthful subjects, certain patient populations and relevance of coagulation monitoring.6-Fluoro-2,3-dihydrobenzofuran Chemical name Thromb J.926659-01-0 structure 2013;11(1):10.PMID:23710097 four. Agency EM. Pradaxa [dabigatran etexilate], solution details. http://www. ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/ human/000829/WC500041059.pdf. Accessed 28 september 2015. 5. Agency EM. Xarelto [rivaroxaban], solution facts. http://www.ema. europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/ human/000944/WC500057108.pdf. Accessed 17 July 2015. 6. Agency EM. Eliquis [apixaban], product details. http://www.ema.europa. eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/ 002148/WC500107728.pdf Accessed 29 October 2015. 19.20.21.22.24.25.26.27. 28.Agency EM. Lixiana [edoxaban], item information.. http://www.ema. europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/ human/002629/WC500189045.pdf. Accessed three July 2015. Ebner M, Birschmann I, Peter A, et al. Point-of-care testing for emergency a.